Article
Xconomy: Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout
Rating:
0.0
Views:
114
Likes:
1
Library:
1
Gilead Sciences is acquiring Immunomedics in a $21 billion deal, the latest in a string of transactions the company has made to bolster its cancer drug
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value